Application of P7C3 in preparation of pharmaceutical preparation for inhibiting hepatic fibrosis

By targeting eIF4A1 with the small molecule compound P7C3 to inhibit the activation of hepatic stellate cells, a variety of drug formulations were prepared, which solved the problem of the lack of effective treatment for liver fibrosis in the existing technology and achieved effective inhibition of liver fibrosis and functional improvement.

CN121129836APending Publication Date: 2025-12-16CHONGQING UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202511377376.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-25
Publication Date
2025-12-16

AI Technical Summary

Technical Problem

Currently, there are no effective drugs for treating liver fibrosis, especially those that can inhibit the activation of hepatic stellate cells, and existing treatment options are insufficient to stop the progression of liver fibrosis.

Method used

Using the small molecule compound P7C3 and its combinations, various pharmaceutical preparations such as tablets and capsules are prepared by targeting eIF4A1 to inhibit the activation of hepatic stellate cells. These preparations are used for oral or injectable administration. Combined with other anti-fibrotic drugs such as methotrexate and mycophenolate mofetil, these preparations can inhibit liver fibrosis and diseases related to abnormal expression of eIF4A1.

Benefits of technology

P7C3 significantly inhibits the activation and proliferation of hepatic stellate cells, reduces the accumulation of extracellular matrix, improves liver function in mouse models of liver fibrosis, reduces serological indicators, alleviates liver fibrosis, and provides an effective treatment option for liver fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121129836A_ABST
    Figure CN121129836A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of a small molecule compound P7C3 in preparation of a pharmaceutical preparation for inhibiting hepatic fibrosis. According to the invention, a CCl4-induced hepatic fibrosis mouse model is used for verifying the treatment effect of P7C3 on hepatic fibrosis. Meanwhile, the influence of P7C3 on HSC activation and proliferation is verified, eIF4A1 is a direct target of P7C3 for inhibiting HSC activation, and P7C3 is a promising anti-hepatic fibrosis therapeutic drug and an effective eIF4A1 inhibitor.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of biological medicine, and particularly relates to application of a small molecule compound P7C3 in preparation of a medicine preparation for inhibiting liver fibrosis. BACKGROUND

[0002] The liver is an organ mainly for metabolism, and its functions are complex, including bile secretion, protein synthesis, storage of various nutrients, detoxification, and immune defense. Common causes of liver fibrosis include chronic viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, cholestasis, parasitic diseases (mainly schistosomiasis), and autoimmune diseases. Under the continuous stimulation of the causes, the liver damage with fibrosis is aggravated, and eventually develops into severe liver disease. Therefore, it is particularly important to take timely intervention measures before liver fibrosis has evolved to a pathological stage that cannot be reversed. Liver fibrosis is a result of wound healing response of the liver to repeated injury. The characteristic of liver fibrosis is the excessive accumulation of extracellular matrix (ECM), which destroys the physiological structure of the liver. The development of liver fibrosis involves multiple types of cells, including key hepatic stellate cells (HSCs), the activation of hepatic stellate cells (HSCs) is considered to be the core event of fibrosis. In addition, the liver cells, endothelial cells, and liver macrophages adjacent to the hepatic stellate cells also participate in the development process of liver fibrosis, and these cells have complex interactions with the hepatic stellate cells to cause scarring to respond to continuous injury. Therefore, one of the most effective strategies for liver fibrosis treatment is to inhibit the activation and proliferation of hepatic stellate cells. However, there is currently no effective treatment. Therefore, it is urgent to find new drugs with good treatment effect and clear mechanism of action.

[0003] P7C3 is a small molecule aminopropyl carbazole chemical, which was first discovered and synthesized by UT Southwestern Medical Center in the United States. P7C3 has oral bioavailability, and is still non-toxic even at several times the effective dose. Recent studies have shown that P7C3 is not limited to the protection of the nervous system, and also has an improvement effect on retinal degeneration, various traumatic brain injury models, type 2 diabetes, ionizing radiation-induced bone loss, and other diseases. In addition, a series of P7C3 derivatives show good pharmacological activity, such as the derivative P7C3-A20 has a significant protective effect on fatty liver.

[0004] Activation and transdifferentiation of hepatic stellate cells are central to liver fibrosis and a common pathology in liver fibrosis caused by various types of liver injury. Under normal circumstances, hepatic stellate cells are in a resting state and rich in vitamin A lipid droplets. Under continuous liver injury stimulation, hepatic stellate cells are activated and differentiate into myofibroblasts, acquiring a typical "myofibroblast-like cell" phenotype: characterized by reduced or absent intracellular lipid droplets, increased rough endoplasmic reticulum, well-developed Golgi apparatus, expression of α-smooth muscle actin (α-SMA), and synthesis of large amounts of extracellular matrix (ECM) components (including type I, III, and IV collagen, fibronectin, and laminin). Therefore, inhibiting hepatic stellate cell activation has become an effective strategy for treating liver fibrosis, and screening small molecules that inhibit hepatic stellate cell activation is currently a top priority.

[0005] Therefore, this invention explores the mechanism of action of P7C3 small molecule compounds in inhibiting liver fibrosis, thereby providing new ideas for the preparation of treatments for liver fibrosis. Summary of the Invention

[0006] In a first aspect, the present invention provides the application of a small molecule compound P7C3 and its composition in the preparation of a pharmaceutical formulation for treating liver fibrosis, characterized in that the chemical structural formula of the small molecule compound P7C3 is: .

[0007] Furthermore, the small molecule compound P7C3 and its compositions contain other anti-fibrotic active pharmaceutical ingredients.

[0008] Furthermore, the active pharmaceutical ingredient includes drugs that inhibit liver fibrosis inflammation or inhibit the proliferation and biochemical activity of hepatic stellate cells.

[0009] Furthermore, the active drug is selected from one or more of methotrexate, mycophenolate mofetil, glucocorticoids, propranolol, and carvedilol.

[0010] Furthermore, the pharmaceutical preparation is selected from one or more of tablets, capsules, pills, oral liquids, lozenges, granules, and pills.

[0011] Furthermore, the pharmaceutical preparation can be applied to individuals requiring treatment via oral, intraperitoneal, subcutaneous, intravenous, intramuscular, or mucosal administration routes, depending on the dosage form.

[0012] Secondly, the present invention provides an eIF4A1 target inhibitor, characterized in that the eIF4A1 target inhibitor contains a small molecule compound P7C3, the chemical structural formula of which is: .

[0013] Furthermore, the eIF4A1 target inhibitor also contains a pharmaceutically acceptable carrier.

[0014] Thirdly, the present invention provides the application of a small molecule compound P7C3 and its composition in the preparation of a pharmaceutical formulation for treating diseases related to the abnormal expression of the eIF4A1 target, characterized in that the chemical structural formula of the small molecule compound P7C3 is: .

[0015] Furthermore, the small molecule compound P7C3 and its compositions contain other pharmaceutically acceptable carriers.

[0016] Furthermore, the diseases associated with abnormal expression of the eIF4A1 target are selected from one or more of breast cancer, melanoma, neuroblastoma, renal cell carcinoma, and hepatocellular carcinoma.

[0017] Furthermore, the small molecule compound P7C3 inhibits the abnormal expression of the eIF4A1 target by targeting eIF4A1.

[0018] Beneficial effects of this invention: This invention uses a CCl4-induced liver fibrosis mouse model to verify the therapeutic effect of P7C3 on liver fibrosis. Simultaneously, it verifies the effect of P7C3 on HSC activation and proliferation, and eIF4A1 is a direct target of P7C3 in inhibiting HSC activation, revealing P7C3 as a promising anti-liver fibrosis therapeutic agent and an effective eIF4A1 inhibitor. Attached Figure Description

[0019] Figure 1 Effects of P7C3 on LX-2 cell viability and proliferation.

[0020] Figure 2 Effect of P7C3 on LX-2 cell activation.

[0021] Figure 3 eIF4A1 is a direct target of P7C3.

[0022] Figure 4 P7C3 downregulates eIF4A1 expression, inhibiting LX-2 cell activation.

[0023] Figure 5 The effect of P7C3 on CCl4-induced liver fibrosis. Detailed Implementation

[0024] Reagents and materials: P7C3 (99.99% purity) was purchased from Selleck (Shanghai, China). Aspartate aminotransferase (AST / GOT), alanine aminotransferase (ALT / GPT), and hydroxyproline (Hyp) assay kits were purchased from Nanjing Jiancheng Biotechnology Institute (Nanjing, China). Antibodies used were: COL1A1 (ET1609-68, HUABIO, China), Fibronectin (FN, A12932, ABclonal, China), eIF4A1 (A23514, ABclonal, China), GAPDH (A19056, ABclonal, China), and secondary antibody (AS014, ABclonal, China).

[0025] The mice used in this invention were obtained from the Experimental Animal Center of Chongqing Medical University (Chongqing, China). The animal experimental design was reviewed and approved by the Animal Experiment Ethics Committee of Chongqing Medical University (Approval No.: IACUC-CQMU-2025-05001). The entire experimental process was conducted under standard conditions.

[0026] Example 1: Hepatic stellate cell culture and viability assay LX-2 is an immortalized human hepatic stellate cell line derived from Guangzhou Cellcook Biotech Co., Ltd. (Guangzhou, China). LX-2 cells were cultured in high-glucose DMEM (VivaCell, Shanghai, China) containing 10% fetal bovine serum and 1% penicillin-streptomycin solution and stored in a 37 °C incubator with 5% CO2. LX-2 cells were passaged regularly every two days.

[0027] To assess the viability of LX-2 cells, cell counting kit-8 (CCK-8) (TargetMol, China) was used. Sterile PBS was filled into the corner wells of 96-well plates, and LX-2 cells were seeded in the center wells at a density of 4000 cells / well. After 12 hours of adhesion, cells were treated with different concentrations of P7C3 (0, 5, 10, and 20 µM). After approximately 48 hours of treatment, 10 µL of CCK-8 reagent was added to each well, and the cells were incubated in a cell culture incubator for 2.5 hours. The absorbance of each well at 450 nm was measured using a microplate reader (BioTek, Winooski, VT, USA).

[0028] Results: CCK8 assay results showed that after 48 hours of P7C3 intervention, LX-2 cell viability gradually decreased with increasing P7C3 concentration. Figure 1 A).

[0029] Example 2 Cell proliferation experiment The effect of P7C3 on LX-2 cell proliferation was assessed using the BeyoClick™ EdU-594 Cell Proliferation Detection Kit (Beyotime, Shanghai, China). Appropriate numbers of LX-2 cells were seeded in 6-well plates overnight and then treated with different concentrations of P7C3 (0, 5, 10, and 20 µM) for 48 hours. Then, 10 µM of 5-ethynyl-2'-deoxyuridine (EdU) reagent was added to each well, and the cells were incubated for 2 hours. After incubation, DMEM and free EdU probes were removed, and cells were fixed with 4% paraformaldehyde at room temperature for 10 minutes, washed three times, and then incubated with PBS containing 0.3% Triton X-100 at room temperature for 10 minutes. After Hoechst 33342 staining for 10 minutes, fluorescence detection and image collection were performed using a fluorescence microscope, and EdU-positive cells were counted using ImageJ software.

[0030] The results showed that the proportion of EdU-positive cells decreased significantly with increasing P7C3 concentration, especially in the 10 μM and 20 μM groups. Figure 1 B, C).

[0031] Example 3: Effect of P7C3 on HSC activation HSC activation is a key factor in the development of liver fibrosis, and inhibiting HSC activation has become an effective strategy for treating liver fibrosis. To better demonstrate the role of P7C3 in the treatment of liver fibrosis, the effect of P7C3 on HSC activation was determined.

[0032] qPCR results showed that P7C3 concentration-dependently reduced the mRNA levels of COL1A1 and FN1, decreasing them by 50% and 67%, respectively, at a concentration of 20 μM. Figure 2 A, B). Furthermore, Western blotting also confirms this trend ( Figure 2 (CE). It is evident that P7C3 inhibits HSC activation.

[0033] Example 4: Target Identification of P7C3 for Inhibiting HSC Activation The method used was a combination of CETSA and LC-MS / MS (CETSA-MS). First, two equal volumes of LX-2 cells were incubated with P7C3 and DMSO for 2 h, respectively, followed by heat shock at 60°C. Then, the differentially expressed protein content between the two groups was quantified by liquid chromatography-tandem mass spectrometry (LC-MS / MS). Figure 3 A). LC-MS / MS analysis showed that 52 proteins with enhanced thermostability were identified in P7C3-treated LX-2 cells. Figure 3B). Intersection analysis of the 52 candidate targets with enhanced thermal stability and the 577 potential targets obtained from the Human Proteome Microarray (HuProt) revealed that eIF4A1 was the only intersecting protein. Figure 3 (C), which suggests that eIF4A1 may be a direct target of P7C3 in inhibiting the proliferation and activation of LX-2 cells.

[0034] This result was confirmed by CETSA and DARTS experiments. In the CETSA experiment, at 50 or 60°C, the eIF4A1 protein in the P7C3-treated group showed significant thermostability compared to the DMSO control group. Figure 3 D, E). Similarly, in the DARTS experiment, at a streptomycin ratio of 1:1000, treatment with P7C3 significantly reduced the sensitivity of eIF4A1 protein to streptomycin. Figure 3 (F, G). These experimental results indicate that P7C3 can directly bind to the eIF4A1 protein in LX-2 cells.

[0035] Example 5: P7C3 regulates eIF4A1 expression to inhibit hepatic stellate cell activation The effect of P7C3 on eIF4A1 expression was examined by Western blotting. The results showed that P7C3 downregulated eIF4A1 protein levels in a dose-dependent manner. Figure 4 A, B). Subsequently, shRNAs specifically knocking down eIF4A1 were synthesized. Compared with the control group, both shRNAs significantly reduced eIF4A1 protein expression, indicating that eIF4A1 was successfully knocked down. Simultaneously, after eIF4A1 knockdown, the levels of COL1A1 and FN1 in LX-2 cells decreased ( Figure 4 (C, D) The results indicate that eIF4A1 is involved in the regulation of hepatic stellate cell activation, and P7C3 inhibits hepatic stellate cell activation by inhibiting eIF4A1 expression, suggesting the potential of eIF4A1 as a therapeutic target for liver fibrosis.

[0036] Example 6: P7C3 alleviates carbon tetrachloride (CCl4)-induced liver fibrosis in mice. The anti-fibrotic effect of P7C3 in vivo was examined using a classic CCl4-induced liver fibrosis mouse model. Histopathological analysis was performed first. Hematoxylin and eosin (H&E) staining results showed that, compared with the control group, the CCl4-induced model group exhibited significant changes in hepatocyte morphology, including hepatocyte vacuolation and disordered arrangement, as well as disordered lobular structure. The P7C3 treatment groups (10 and 20 mg / kg) showed a dose-dependent improvement in CCl4-induced hepatocyte morphological abnormalities compared to the model group. Figure 5A). Masson and Sirius red staining showed that P7C3 significantly reduced collagen fiber deposition in the liver ( Figure 5 A, B). Liver injury was assessed using the liver weight to body weight ratio (liver-to-body weight ratio). Results showed that the liver-to-body weight ratio was significantly higher in the model group compared to the control group, while it decreased in the P7C3 treatment group in a dose-dependent manner. Figure 5 C). Furthermore, serological analysis revealed that serum ALT and AST levels were significantly reduced after P7C3 intervention. Figure 5 Similarly, the levels of hydroxyproline were also significantly reduced (D, E). Figure 5 F).

[0037] These results indicate that P7C3 significantly improves liver function in mice with CCl4-induced liver fibrosis. Furthermore, Western blotting results showed that, compared with the model group mice, P7C3 significantly reduced the protein levels of COL1A1, FN, and eIF4A1 in liver tissue (e.g., ...). Figure 5 (GJ). These results indicate that P7C3 alleviates CCl4-induced liver fibrosis.

Claims

1. The application of a small molecule compound P7C3 and its composition in the preparation of pharmaceutical formulations for treating liver fibrosis, characterized in that, The chemical structural formula of the small molecule compound P7C3 is as follows: 。 2. The use of the small molecule compound P7C3 and its composition as described in claim 1 in the preparation of pharmaceutical formulations for treating liver fibrosis, characterized in that, The small molecule compound P7C3 and its compositions contain other active anti-fibrotic drugs.

3. The use of the small molecule compound P7C3 and its composition as described in claim 1 in the preparation of pharmaceutical formulations for treating liver fibrosis, characterized in that, The active pharmaceutical ingredient includes drugs that inhibit liver fibrosis inflammation or inhibit the proliferation and biochemical activity of hepatic stellate cells.

4. The use of the small molecule compound P7C3 and its composition as described in claim 1 in the preparation of pharmaceutical formulations for treating liver fibrosis, characterized in that, The active drug is selected from one or more of methotrexate, mycophenolate mofetil, glucocorticoids, propranolol, and carvedilol.

5. The use of the small molecule compound P7C3 and its composition as described in claim 1 in the preparation of pharmaceutical formulations for treating liver fibrosis, characterized in that, The pharmaceutical preparation is selected from one or more of the following: tablets, capsules, pills, oral liquids, lozenges, granules, and pills.

6. An eIF4A1 target inhibitor, characterized in that, The eIF4A1 target inhibitor contains a small molecule compound P7C3, the chemical structural formula of which is: 。 7. The eIF4A1 target inhibitor as described in claim 6, characterized in that, The eIF4A1 target inhibitor also contains a pharmaceutically acceptable carrier.

8. The use of a small molecule compound P7C3 and its composition in the preparation of a pharmaceutical formulation for treating diseases related to the abnormal expression of the eIF4A1 target, characterized in that, The chemical structural formula of the small molecule compound P7C3 is as follows: 。 9. The use of the small molecule compound P7C3 and its composition as described in claim 8 in the preparation of pharmaceutical formulations for treating diseases related to the abnormal expression of the eIF4A1 target, characterized in that, The diseases associated with abnormal expression of the eIF4A1 target are selected from one or more of breast cancer, melanoma, neuroblastoma, renal cell carcinoma, and hepatocellular carcinoma.

10. The use of the small molecule compound P7C3 and its composition as described in claim 8 in the preparation of pharmaceutical formulations for treating diseases related to the abnormal expression of the eIF4A1 target, characterized in that, The small molecule compound P7C3 inhibits the abnormal expression of the eIF4A1 target by targeting eIF4A1.

Citation Information

Cited By

  • Culture medium and culture method of podocyte fate organoid

    CN121950665A